Prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines are highly
effective. The available evidence suggests that neutralising antibody is the mechanism of …

… of the human papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US
adolescents has increased but remains low compared with other recommended vaccines. …

… We describe a simplified model, based on the current economic and health effects of
human papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old …

… Cervarix® product information: human papillomavirus vaccine type 16 and 18 (Recombinant
AS04 adjuvanted), 2007. Boronia, Victoria, Australia, 2007 (http://www.gsk.com.au/…

… Identification of human papillomavirus (… vaccines to control HPV-associated malignancies.
Excitement has been generated by the commercialization of two preventive L1-based vaccines…

… increase adolescent human papillomavirus vaccination rates … support the National HPV
Vaccination Roundtable and is co-… initiatives to increase human papillomavirus vaccination. The …

… , two different human papillomavirus virus (HPV) vaccines were licensed for use: a
quadrivalent (qHPVv) and a bivalent (bHPVv) vaccine. Since 2008, HPV vaccination programmes …

… definitively linked to genital human papillomavirus (HPV) infections, a … Human papillomaviruses
are non-enveloped double … Among the nearly 100 types of papillomaviruses molecularly …

… Vaccination against human papillomavirus (HPV) is routinely recommended at age 11 or
12 years. Catch-up recommendations apply to persons not vaccinated at age 11 or 12 years. …

… , the failure to develop successful vaccines against the most common … vaccines against
genital human papillomaviruses (HPVs). In recently concluded clinical trials, these vaccines were …